We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
+10.57%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$2.32B
AUM Growth
+$241M
(+12%)
Cap. Flow
+$64.7M
Cap. Flow
% of AUM
2.79%
Top 10 Holdings %
Top 10 Hldgs %
43.21%
Holding
64
New
9
Increased
30
Reduced
18
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$66.8M |
| 2 |
Celldex Therapeutics
CLDX
|
+$33M |
| 3 |
KERX
Keryx Biopharmaceuticals Inc
KERX
|
+$32.9M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$29M |
| 5 |
Ionis Pharmaceuticals
IONS
|
+$27.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Incyte
INCY
|
+$58.3M |
| 2 |
ARIA
Ariad Pharmaceuticals Inc
ARIA
|
+$55.4M |
| 3 |
Gilead Sciences
GILD
|
+$52.6M |
| 4 |
MDVN
MEDIVATION, INC.
MDVN
|
+$37.8M |
| 5 |
VPHM
VIROPHARMA INC
VPHM
|
+$21.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 89.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HOLX
51
DELISTED
Hologic
HOLX
| $5.35M | 0.23% |
239,485
-137,047
| -36% | -$3.02M |
|
|
NVO
52
Novo Nordisk
NVO
$225B
| $3.72M | 0.16% |
201,260
+3,500
| +2% | +$61K |
|
|
RLYP
53
DELISTED
RELYPSA INC COM
RLYP
| $1.25M | 0.05% |
+50,000
| New | +$1.03M |
|
54
PTC Therapeutics
PTCT
$6.25B
| $976K | 0.04% |
57,519
| – | – |
|
55
Novartis
NVS
$304B
| $973K | 0.04% |
13,504
+1,228
| +10% | +$85.4K |
|
56
Karyopharm Therapeutics
KPTI
$161M
| $802K | 0.03% |
+2,333
| New | +$644K |
|
57
Tandem Diabetes Care
TNDM
$1.22B
| $515K | 0.02% |
+2,000
| New | +$458K |
|
|
XLRN
58
DELISTED
Acceleron Pharma
XLRN
| $389K | 0.02% |
+9,827
| New | +$237K |
|
|
WX
59
DELISTED
WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS
WX
| $230K | 0.01% |
+6,000
| New | +$189K |
|
60
Pfizer
PFE
$144B
| – | – |
-727,973
| Closed | -$19.8M |
|
|
ACHN
61
DELISTED
Achillion Pharmaceuticals
ACHN
| – | – |
-384,300
| Closed | -$1.16M |
|
|
ARIA
62
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| – | – |
-3,008,541
| Closed | -$55.4M |
|
|
VPHM
63
DELISTED
VIROPHARMA INC
VPHM
| – | – |
-556,024
| Closed | -$21.8M |
|
|
EVAC
64
DELISTED
EDWARDS GROUP LTD ADR (CYM)
EVAC
| – | – |
-196,669
| Closed | -$13.7M |
|
Similar funds
RIP
LFWA
CF
WIM
MW
AFC
AAA
TGM
Sectoral Asset Management's Q4 2013 Portfolio in Review
As of Q4 2013, Sectoral Asset Management held 64 positions worth $2.32B, up 12% from $2.08B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Sectoral Asset Management's Q4 2013 filing shows 9 new, 30 increased, 18 reduced and 5 closed positions. Its largest new stake was Keryx Biopharmaceuticals Inc: 2,758,950 shares worth $35.7M. The largest sale was Incyte, an estimated $58.3M.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 86% a quarter earlier.
- Sectoral Asset Management's largest Q4 2013 buy was Keryx Biopharmaceuticals Inc: 2,758,950 shares worth $35.7M.
- Sectoral Asset Management added most to Biogen in Q4 2013, an estimated $66.8M increase.
- Sectoral Asset Management's biggest Q4 2013 reduction was Incyte, cutting an estimated $58.3M.
- Sectoral Asset Management fully exited Ariad Pharmaceuticals Inc in Q4 2013, selling an estimated $55.4M.
- Sectoral Asset Management's ten largest holdings make up 43% of its $2.32B portfolio in Q4 2013.
- Sectoral Asset Management opened 9 new positions and closed 5 in Q4 2013.
- Sectoral Asset Management's portfolio value rose 12% quarter-over-quarter to $2.32B.
Based on Sectoral Asset Management's 13F filing for Q4 2013, filed 12 Feb 2014.